Outcomes of atrial fibrillation in patients with COVID-19 pneumonia: A systematic review and meta-analysis

Atrial fibrillation in COVID-19 patients receiving remdesivir, matched case-control analysis

“…We have read with great interest the review article by Chen et al [ 1 ] summarizing concerns regarding atrial fibrillation (AF) in COVID-19 patients. Although no remdesivir related concerns were highlighted by the authors, it should be noted that bradycardia has been consistently associated with remdesivir [ 2 ] and patients able to develop bradycardia might have a good prognosis with less respiratory deterioration and lower mortality [ 3 ].…”

Global burden of atrial fibrillation/flutter due to high systolic blood pressure from 1990 to 2019: estimates from the global burden of disease study 2019

“…Therefore, further efforts should be made to help physicians actively initial and intensify BP‐lowering medication in Sub‐Saharan Africa to achieve optimal BP control. At the same time, evidence shows that acute SARS‐CoV‐2 infection may increase the susceptibility to AF and promote the evolution of a prothrombotic state 29,30 . These regions with limited resources are suffering a double whammy in the AF/AFL burden.…”

The Cardiovascular Manifestations of COVID-19

“…Atrial fibrillation and flutter (AF) are the most commonly encountered cardiac dysrhythmias in the United States 60 and are associated with an increased risk of stroke, transient ischemic attack (TIA), and other arterial emboli. Both the risk of mortality 61 and thromboembolic complications 62 are higher among patients with COVID-19 who also have preexisting AF. In a large systematic review and analysis of 19 studies totaling 21,653 patients hospitalized with COVID-19, the pooled prevalence of AF was 11%.…”